Purpose: To describe the efficacy of episcleral brachytherapy in a choroidal melanoma and circumscribed hemangioma arising in both eyes of the same patient.
Case Report: We present the case of a 47 year old man who presented decreased visual acuity a few months preceding initial consult. On fundoscopy, he presented a melanotic lesion in the right eye, and a red-orange choroidal mass in the macular area of the left eye.
Material And Methods: B scan-ultrasound, fluorescein, and indocyanine green angiography, confirmed the diagnosis of choroidal melanoma in the right eye, and circumscribed choroidal hemangioma in the left eye. Episcleral brachytherapy with (125)I was performed in both eyes consecutively.
Results And Conclusions: Bilateral episcleral brachytherapy successfully treated both tumors, preserving the eyes and useful visual function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899632 | PMC |
| http://dx.doi.org/10.5114/jcb.2013.38523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery.
Am J Ophthalmol
December 2024
Department of Radiation Oncology (L.C., M.S., H.L., Y.C., W.S.), Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:
Purpose: Uveal melanoma (UM) represents the most prevalent and aggressive intraocular malignancy in adults. This study examined the outcomes of patients diagnosed with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel Linear Accelerator (LINAC)-based frameless technique.
Design: Retrospective, interventional case series.
Clinical Features and Initial Management Outcomes of Uveal Melanomas in a Single Tertiary Center in Egypt.
Ocul Oncol Pathol
December 2024
Cairo University Ocular Oncology Service, Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Article Synopsis
- The study focuses on the demographic, clinical, and management outcomes of patients with uveal melanoma at a tertiary center in Egypt over five years.
- A total of 93 patients were treated, with most tumors being choroidal, and common treatments included brachytherapy and gamma knife radiosurgery, leading to a successful globe salvage rate of 84.62%.
- The conclusion emphasizes the importance of timely referrals and proper assessments to improve treatment success and highlights the need for advanced tumor patients to consider enucleation to lower the risk of metastasis and mortality.
Yttrium-90 (Y) brachytherapy for squamous carcinoma: Treatment of the conjunctiva, cornea, and sclera.
Am J Ophthalmol Case Rep
December 2024
Duke University Eye Center, 2351 Erwin Road, Durham, NC, 27710, USA.
Purpose: Patients with conjunctival squamous cell carcinoma that present with persisting disease or recurrence following topical chemotherapy and/or surgery especially when invading the sclera are challenging to treat. Herein, we describe the use of high-dose-rate (HDR), FDA-cleared, yttrium-90 (Y) plaque brachytherapy for such lesions.
Observation: Three cases of invasive conjunctival squamous cell carcinoma that had exhibited a poor response or recurrence following topical chemotherapy and/or surgery are described.
External Beam Radiotherapy in the Management of Uveal Melanoma.
Curr Treat Options Oncol
July 2024
Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey.
Uveal melanoma is the most common primary ocular tumor in adults. With the evidence demonstrating that episcleral plaque brachytherapy (EPB) has similar survival rates as enucleation in the Collaborative Ocular Melanoma Study (COMS), eye-sparing treatments have come to the fore today. External radiotherapy techniques (proton beam radiotherapy and stereotactic radiosurgery/fractionated stereotactic radiosurgery) are an important treatment option for globe-sparing treatments.
View Article and Find Full Text PDFHigh-Dose-Rate Yttrium-90 (Y) Episcleral Plaque Brachytherapy for Iris and Iridociliary Melanoma.
Ophthalmol Sci
March 2024
The Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, New York.
Article Synopsis
- - This pilot study explored the use of high-dose-rate yttrium-90 (Y) plaque brachytherapy as a treatment for iris and iridociliary melanoma in six patients diagnosed through clinical examination or biopsy.
- - The procedure involved staging tumors and conducting the treatment with a focus on various factors such as tumor size and patient demographics, while also monitoring for complications like inflammation or cataract progression.
- - Results showed effective tumor control with fast treatment times (average 8.8 minutes) and minimal side effects, indicating that high-dose-rate brachytherapy could be a promising option for managing small melanomas without extensive surgical procedures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!